Latest News on DNLI

Financial News Based On Company


Advertisement
Advertisement

Form 4 Denali Therapeutics Inc: Alexander O. Schuth (COFO and Secretary) For: 17 November By Investing.com

https://za.investing.com/news/stock-market-news/form-4-denali-therapeutics-inc-alexander-o-schuth-cofo-and-secretary-for-17-november-93CH-4587913
This article reports on a Form 4 filing for Denali Therapeutics Inc., detailing an insider transaction by Alexander O. Schuth, the company's COFO and Secretary, on November 17th. The brief announcement provides the essential details of the filing, indicating transparency in executive stock movements.

DNLI: AVLAYAH launch momentum builds as Hunter, Sanfilippo and Alzheimer’s programs advance

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4664607:0-dnli-avlayah-launch-momentum-builds-as-hunter-sanfilippo-and-alzheimer-s-programs-advance/
Denali Therapeutics Inc. (DNLI) is seeing strong momentum for its AVLAYAH launch, with sales exceeding prior guidance and a goal to lead the Hunter market next year. The company anticipates key data milestones for its COMPASS, Sanfilippo, and Alzheimer’s programs in 2027 and 2028. This information is based on the UBS Global Biopharma Conference 2026 audio transcript from November 17, 2026.

T. Rowe Price reports 19.6M shares in Denali Therapeutics (DNLI), amending its ownership disclosure.

https://www.stocktitan.net/sec-filings/DNLI/schedule-13g-a-denali-therapeutics-inc-amended-passive-investment-dis-9cf369a145ba.html
T. Rowe Price Investment Management, Inc. has filed an amended ownership report for Denali Therapeutics (DNLI), disclosing beneficial ownership of 19,634,011 common shares, representing a 12.3% stake. The report indicates sole voting power over 18,904,392 shares and sole dispositive power over all 19,634,011 shares, with no shared powers. T. Rowe Price explicitly denies beneficial ownership, stating the filing is not an admission of such.

Denali Therapeutics Targets All Eligible Hunter Disease Patients as Pipeline Milestones Near

https://www.tradingview.com/news/marketbeat:6e8c71087094b:0-denali-therapeutics-targets-all-eligible-hunter-disease-patients-as-pipeline-milestones-near/
Denali Therapeutics is actively pursuing a strategy to treat all eligible Hunter disease patients in the U.S. with its AVLAYAH treatment, which generated $7.8 million in its second quarter after launch. The company is also advancing multiple pipeline programs, including treatments for Sanfilippo syndrome, Pompe disease, and Alzheimer's disease, with significant data readouts and regulatory filings anticipated in the coming years. Denali extended its progranulin study and plans to present data at scientific conferences, while also exploring potential partnerships for its Alzheimer's programs.

Denali Therapeutics' AVLAYAH launch drives $7.8M revenue with strong patient and payer support

https://pluang.com/en/news-feed/denali-therapeutics-dnli-peluncuran-avlayah-pendapatan-komersial-kuat
Denali Therapeutics reported a successful launch for its drug AVLAYAH, generating $7.8 million in revenue during its second quarter on the market. The drug has garnered substantial support from patients, physicians, and payers, with approximately 70% commercial coverage and Medicaid access in 20 states. This strong market entry is attributed to collaborative backing, and the company plans to advance its pipeline with future data readouts.
Advertisement

Denali Therapeutics Inc. Stock 12‑Month Price Target Cut to $35.82, Implies 90% Upside

https://www.tradingview.com/news/tradingview:a61d9f14cd324:0-denali-therapeutics-inc-stock-12-month-price-target-cut-to-35-82-implies-90-upside/
Denali Therapeutics Inc. (DNLI) has seen its average 12-month price target cut slightly from $36.12 to $35.82 by 17 analysts, with forecasts ranging from $24 to $46 per share. This updated target suggests a potential upside of approximately 90% based on the Nov. 12 closing price. The consensus rating for Denali Therapeutics Inc. remains a "Buy" from 21 covering analysts.

Morgan Stanley maintains Denali Therapeutics at Overweight, lowers price target to $37 from $42

https://www.tradingview.com/news/tradingview:b6805d45ebaf9:0-morgan-stanley-maintains-denali-therapeutics-at-overweight-lowers-price-target-to-37-from-42/
Morgan Stanley reiterated its "Overweight" rating for Denali Therapeutics but reduced its price target to $37 from $42, a decrease of 11.9%. This new price target suggests a potential upside of 95.9% from the stock's closing price of $18.89 on November 12. Other recent analyst actions on Denali Therapeutics show price targets ranging from $24 to $42.

Wells Fargo initiates Denali Therapeutics stock with overweight rating

https://www.investing.com/news/analyst-ratings/wells-fargo-initiates-denali-therapeutics-stock-with-overweight-rating-93CH-5024687
Wells Fargo has initiated coverage on Denali Therapeutics (NASDAQ:DNLI) with an overweight rating and a $35.00 price target, citing an approaching inflection point for its transferrin receptor technology. The firm highlights the approval of Avlayah and constructive FDA feedback on zafinofusp as key drivers, along with validating data from Roche's trontinemab in Alzheimer’s disease. Despite the smaller markets of Hunter and Sanfilippo syndromes, Wells Fargo anticipates that advancements in assets for larger markets like Alzheimer's will further boost the stock, which is currently considered undervalued by InvestingPro.

Wells Fargo initiated coverage on Denali Therapeutics with a new price target

https://www.quantisnow.com/insight/wells-fargo-initiated-coverage-on-denali-therapeutics-with-a-new-6789396
Wells Fargo has initiated coverage on Denali Therapeutics (DNLI) with an "Overweight" rating and a price target of $35.00. Historically, Denali Therapeutics' stock has shown varied reactions to analyst coverage notes, closing higher 2 out of 4 times after previous notes since January 2026. The article also provides historical context for DNLI's stock performance after earlier headlines, showing a median move of 3.1% in either direction across 21 sessions.

Denali Therapeutics stock: late Lang & Schwarz quote

https://www.ad-hoc-news.de/boerse/news/corporate-news/denali-therapeutics-stock-late-lang-schwarz-quote/70488622
Denali Therapeutics stock was quoted at EUR 17.80 on Lang & Schwarz on November 10, 2026, at 10:18 p.m. CET. The company focuses on developing medicines for serious diseases affecting the brain and body, utilizing its TransportVehicle platform to help biotherapeutics cross biological barriers. Its pipeline includes treatments for neurodegenerative diseases and lysosomal storage disorders, which remains a key focus for investors.
Advertisement

(DNLI) Movement Within Algorithmic Entry Frameworks

https://news.stocktradersdaily.com/news_release/1/DNLI_Movement_Within_Algorithmic_Entry_Frameworks_111026072201_1794356521.html
This report analyzes Denali Therapeutics Inc. (NASDAQ: DNLI) using AI-generated trading strategies. It highlights a near-term neutral sentiment amidst mid and long-term strength, noting a mid-channel oscillation pattern and an exceptional 52.0:1 risk-reward setup targeting a 16.1% gain. The analysis provides three distinct trading plans: Position Trading, Momentum Breakout, and Risk Hedging, complete with entry, target, and stop levels.

Denali Therapeutics Inc. (4DN.F) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/4DN.F/earnings-calls/
This article provides a detailed overview of Denali Therapeutics Inc. (4DN.F), including its current stock price, historical data, and key financial statistics. It highlights the company's focus on discovering and developing therapeutics for neurodegenerative and lysosomal storage diseases. The report also lists various drug programs in its pipeline and offers performance comparisons against the S&P 500.

Denali Therapeutics Inc. (DNLI) Seasonal returns chart

https://au.finance.yahoo.com/quote/DNLI/seasonality/
This article presents a seasonal returns chart for Denali Therapeutics Inc. (DNLI), showing the average monthly price return from 2017 to 2026. As of the report, Denali Therapeutics Inc. (DNLI) stock was trading at 19.15 USD, down 2.94%. The data is provided by Yahoo Finance, including a snapshot of various market indices and commodities.

Denali Therapeutics Inc. (DNLI) Seasonal returns chart - Yahoo Finance

https://sg.finance.yahoo.com/quote/DNLI/seasonality/
This Yahoo Finance article displays the seasonal returns chart for Denali Therapeutics Inc. (DNLI), showing average monthly price returns from 2017 to 2026. As of the snapshot, DNLI's stock price was $18.49, up 1.59% for the day. The page also provides quick access to various market data and related tickers.

Denali Therapeutics (DNLI) Stock Price, Chart & Analysis

https://www.debelegger.nl/en/stock/DNLI.US
This article provides a detailed analysis of Denali Therapeutics (DNLI) stock, including its latest price, market capitalization, and listing information on NASDAQ. It presents various financial metrics such as quality score, revenue growth, and debt situation, along with an evaluation based on Buffett and Lynch methodologies. The analysis also includes analyst forecasts and several hypothetical price scenarios for the stock.
Advertisement

DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?

https://www.tradingview.com/news/zacks:525af3da4094b:0-dnli-up-7-8-post-q3-earnings-should-you-buy-sell-or-hold-the-stock/
Denali Therapeutics, Inc. (DNLI) reported better-than-expected Q3 earnings, with a narrower loss and higher revenues, driven by the strong commercial uptake of its lead drug, Avlayah. The company's shares surged 27% year-to-date, outperforming the industry, sector, and S&P 500 Index. While Avlayah's launch is a significant catalyst, the sustainability of revenue growth and upcoming clinical readouts for other pipeline candidates will be crucial for future performance.

Denali Therapeutics Inc (DNLI) Q3 2026 Earnings Call Highlights: AVLAYAH Revenue Soars Nearly ...

https://sg.finance.yahoo.com/news/denali-therapeutics-inc-dnli-q3-170531022.html
Denali Therapeutics Inc. reported strong Q3 2026 earnings, with AVLAYAH net product revenue reaching $17.8 million, a nearly five-fold increase from the previous quarter and well above guidance. The company also announced a net income of $70.1 million, primarily due to a $195 million PRV sale, and maintains a strong cash position of approximately $1.01 billion. Commercial coverage for AVLAYAH expanded significantly, and progress was made on other pipeline programs, though some revenue growth was pulled forward, and manufacturing readiness remains a key factor for future BLA submissions.

Denali's $70.1 million profit included a one-time $194 million gain from selling a voucher for faster FDA review.

https://www.stocktitan.net/news/DNLI/denali-therapeutics-reports-third-quarter-2026-financial-results-and-3v4ws89ajrec.html
Denali Therapeutics reported a net income of $70.1 million for Q3 2026, primarily due to a one-time $194.0 million gain from selling a Priority Review Voucher, which reversed a previous year's net loss. The company's AVLAYAH product generated $17.8 million in net product revenue and is projected to reach $30.0 million to $32.0 million in Q4 2026. Denali also provided updates on its clinical programs, including zafinofusp alfa for Sanfilippo syndrome type A, with a BLA submission on track for 2027.

Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

https://www.manilatimes.net/2026/11/04/tmt-newswire/globenewswire/denali-therapeutics-reports-third-quarter-2026-financial-results-and-business-highlights/2461102/amp
Denali Therapeutics announced strong third-quarter 2026 financial results, with net income of $70.1 million, driven by $17.8 million in net product revenue from AVLAYAH® and a $194.0 million gain from a Priority Review Voucher sale, bringing their cash, cash equivalents, and marketable securities to $1.0 billion. The company also provided positive updates on its clinical pipeline, including progress for zafinofusp alfa (MPS IIIA) and several TransportVehicle™ programs expected to generate data in 2027 for Alzheimer's, FTD-GRN, and Pompe diseases. AVLAYAH® (tividenofusp alfa-eknm) was recognized as the "Best Biotechnology Product" of 2026 by The Galien Foundation.

Denali Therapeutics Q4 Results: Sales guidance $30M-$32M beats estimates

https://scanx.trade/stock-market-news/companies/denali-therapeutics-q4-results-sales-guidance-30m-32m-beats-estimates/55291701
Denali Therapeutics reported strong Q3 revenue of $17.778 million, significantly beating analyst estimates, although adjusted EPS missed expectations. The company also issued robust Q4 sales guidance of $30 million to $32 million, which substantially exceeds analyst forecasts, indicating a positive outlook despite the recent earnings miss. This divergence highlights a gap between internal projections and external market sentiment, suggesting higher operating costs in Q3 but strong anticipated performance in Q4.
Advertisement

Denali Therapeutics (DNLI) Swings To Q3 Profit, Is The Upside Already Priced In?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnli/denali-therapeutics/news/denali-therapeutics-dnli-swings-to-q3-profit-is-the-upside-a
Denali Therapeutics (DNLI) reported a swing to profit in Q3 2026, with US$17.78 million in revenue and US$70.13 million in net income. While the stock saw a 3.34% gain on release day and a 30.63% 1-year return, it remains 45% undervalued according to a popular narrative, suggesting potential upside, though a Simply Wall St DCF model indicates it might be slightly overvalued at its current price of $19.49. The company's enzyme transport vehicle franchise targets lysosomal storage disorders with significant market potential.

Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue Estimates

https://uk.finance.yahoo.com/news/denali-therapeutics-inc-dnli-reports-215003286.html
Denali Therapeutics Inc. (DNLI) reported a Q3 loss of $0.64 per share, surpassing the Zacks Consensus Estimate of a $0.69 loss and beating last year's $0.74 loss. The company also posted revenues of $17.78 million, exceeding estimates by 41.88% compared to zero revenues a year ago. Despite outperforming the market year-to-date, the stock holds a Zacks Rank #3 (Hold) due to a mixed trend in earnings estimate revisions.

Denali Therapeutics Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62849030/denali-therapeutics-q3-2026-earnings-call-transcript
Denali Therapeutics reported strong Q3 2026 financial results, with ABLEA net product revenue significantly exceeding expectations at $17.8 million and a Q4 forecast of $30-32 million. The company is advancing its clinical pipeline, including completing a Phase 2 study for Zofenofusp Alpha and progressing Alzheimer’s disease programs, with multiple data readouts anticipated in 2027. Denali's transport vehicle platform is central to its strategy, aiming to deliver brain-penetrant therapies across rare and common neurodegenerative diseases, supported by a strong cash position of approximately $1.01 billion.

Denali Therapeutics Inc. (DNLI) Tops Q3 EPS by 74c

https://www.streetinsider.com/Earnings/Denali+Therapeutics+Inc.+%28DNLI%29+Tops+Q3+EPS+by+74c/27281983.html
Denali Therapeutics Inc. (DNLI) reported robust third-quarter earnings, with an EPS of $0.37, significantly beating the analyst estimate of ($0.37) by $0.74. The company's revenue for the quarter also surpassed expectations, reaching $17.77 million against a consensus estimate of $12.22 million. This strong performance indicates a positive financial quarter for Denali Therapeutics.

Denali's AVLAYAH Launch Blows Past Guidance As Q4 Outlook Nearly Triples, But A Shrinking Stock Prices In Doubt

https://finviz.com/news/415036/denalis-avlayah-launch-blows-past-guidance-as-q4-outlook-nearly-triples-but-a-shrinking-stock-prices-in-doubt
Denali Therapeutics reported strong Q3 2026 revenue of $17.78 million, significantly exceeding expectations, driven entirely by its Hunter syndrome therapy, AVLAYAH. The company also issued a robust Q4 outlook, nearly tripling its previous guidance. Despite this commercial success, Denali's stock price has declined, leading to investor skepticism regarding the sustainability of the launch curve, especially as key patient metrics remain undisclosed.
Advertisement

Hunter syndrome's first new FDA-approved treatment option in nearly 20 years wins a 2026 award

https://www.stocktitan.net/news/DNLI/denali-therapeutics-receives-2026-prix-galien-usa-award-for-avlayah-snzfpxodwm1y.html
Denali Therapeutics has been honored with the 2026 Prix Galien USA award for Best Biotechnology Product for AVLAYAH (tividenofusp alfa-eknm), its treatment for Hunter syndrome. AVLAYAH is the first FDA-approved biologic designed to cross the blood-brain barrier, offering a new treatment option for the neurologic manifestations of this rare neurodegenerative disorder. The award recognizes Denali's pioneering research and its TransportVehicle technology, which enables the delivery of large therapeutic molecules to the brain.

Denali Therapeutics stock draws focus after AVLAYAH award

https://www.ad-hoc-news.de/boerse/news/corporate-news/denali-therapeutics-stock-draws-focus-after-avlayah-award/70436439
Denali Therapeutics' stock is gaining attention after its first approved blood-brain barrier therapy, AVLAYAH, received the 2026 Prix Galien USA biotechnology award. This recognition comes just ahead of the company's third-quarter earnings report on November 3, which will include financial results and business highlights. Continued approval of AVLAYAH, which received accelerated FDA approval, will depend on confirmatory evidence of clinical benefit.

Denali Therapeutics wins 2026 Prix Galien USA Award for AVLAYAH®, first FDA-approved biologic crossing blood-brain barrier

https://pluang.com/en/news-feed/denali-therapeutics-raih-penghargaan-prix-galien-usa-2026-produk-bioteknologi
Denali Therapeutics' AVLAYAH® (tividenofusp alfa-eknm), the first FDA-approved biologic to cross the blood-brain barrier, has won the 2026 Prix Galien USA Award for Best Biotechnology Product. Approved in March 2026 for treating Hunter syndrome in pediatric patients, the drug utilizes Denali’s proprietary TransportVehicle™ technology, marking a significant advancement in delivering therapies for rare genetic and neurodegenerative diseases. This award recognizes AVLAYAH's scientific innovation and its potential to revolutionize patient care.

Denali Therapeutics’ AVLAYAH Wins 2026 Prix Galien Award for Best Biotechnology Product

https://www.quiverquant.com/news/Denali+Therapeutics%E2%80%99+AVLAYAH+Wins+2026+Prix+Galien+Award+for+Best+Biotechnology+Product
Denali Therapeutics' FDA-approved biologic, AVLAYAH (tividenofusp alfa-eknm), has received the "Best Biotechnology Product" award from The Galien Foundation for 2026. This recognition highlights AVLAYAH as the first biologic designed to cross the blood-brain barrier for treating Hunter syndrome, a rare neurodegenerative disorder. The award validates Denali's innovative TransportVehicle™ technology and its potential to develop therapies for a broad range of brain-related diseases, including Alzheimer's.

Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product

https://www.manilatimes.net/2026/10/30/tmt-newswire/globenewswire/denali-therapeutics-receives-2026-prix-galien-usa-award-for-avlayah-tividenofusp-alfa-eknm-as-best-biotechnology-product/2458356/amp
Denali Therapeutics Inc. has been awarded the 2026 Prix Galien USA Award for "Best Biotechnology Product" for AVLAYAH® (tividenofusp alfa-eknm). AVLAYAH is the first FDA-approved biologic designed to cross the blood-brain barrier, offering a new treatment option for the neurologic manifestations of Hunter syndrome. This recognition highlights Denali's pioneering TransportVehicle technology and its potential for addressing a wide range of neurodegenerative diseases.
Advertisement

Wedbush cuts target for Denali Therapeutics stock from USD 27 to USD 23

https://www.ad-hoc-news.de/boerse/news/corporate-news/wedbush-cuts-target-for-denali-therapeutics-stock-from-usd-27-to-usd-23/70423137
Wedbush has reduced its price target for Denali Therapeutics (DNLI) stock from $27 to $23 while maintaining an Outperform rating. This adjustment comes ahead of Denali's third-quarter 2026 earnings report, scheduled for November 3, 2026. The stock is currently trading at EUR 17.28 after hours, up 5.85% against the Frankfurt close, with a market capitalization of $3.1 billion.

Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026

https://news.futunn.com/en/post/1002004491/denali-therapeutics-to-report-third-quarter-2026-financial-results-and
Denali Therapeutics will report its third-quarter 2026 financial results and provide business highlights on November 3, 2026. The company will also host a conference call and webcast to discuss these results.

Wedbush cuts Denali target to USD 23 for Denali Therapeutics stock

https://www.ad-hoc-news.de/boerse/news/corporate-news/wedbush-cuts-denali-target-to-usd-23-for-denali-therapeutics-stock/70406103
Wedbush has lowered its price target for Denali Therapeutics (DNLI) from USD 27.00 to USD 23.00, though it maintained an "Outperform" rating. The biotechnology company is scheduled to report its third-quarter 2026 results on November 3, 2026, with an expected revenue of USD 12.22 million, significantly higher than the previous quarter. Denali's stock was trading at EUR 16.43 on October 24, 2026, and the upcoming earnings report will be a key test for its valuation.

Denali Therapeutics Inc. (DNLI) latest stock news and headlines – Yahoo Finance

https://sg.finance.yahoo.com/quote/DNLI/news/
This Yahoo Finance page provides a compilation of recent news and headlines related to Denali Therapeutics Inc. (DNLI) stock. It includes a summary of the stock's performance, current trading information, and links to articles from various sources such as GlobeNewswire, Zacks, PR Newswire, and Simply Wall St., discussing financial results, market valuations, and pipeline innovations. The page also features a performance overview comparing DNLI's trailing total returns against the S&P 500 benchmark.

Denali Therapeutics Inc. (DNLI) Interactive Stock Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/DNLI/chart/
This page provides an interactive stock chart for Denali Therapeutics Inc. (DNLI) on Yahoo Finance, showing its current trading price and recent performance. It also lists various news articles related to Denali Therapeutics, including upcoming financial results, market analysis, and reports on its product pipeline. The stock is currently trading at $18.52, up 0.60% as of 12:58:31 p.m. EDT.
Advertisement

Denali Therapeutics Inc. Estimates – NASDAQ:DNLI

https://www.tradingview.com/symbols/NASDAQ-DNLI/financials-estimates/
This article provides an overview of Denali Therapeutics Inc. (NASDAQ: DNLI) financials, focusing on actual results and analyst estimates. It allows users to explore reported financial data across income statements, balance sheets, cash flow statements, and valuation metrics. The platform also enables comparison of actual results with average, high, and low estimates, and visualization of trends over time.

Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026

https://www.moomoo.com/news/post/1002066859/denali-therapeutics-to-report-third-quarter-2026-financial-results-and
Denali Therapeutics (NASDAQ: DNLI) announced it will release its third quarter 2026 financial results and provide business highlights after the market closes on Tuesday, November 3, 2026. The company will also host a conference call and webcast on the same day to discuss these results.

DNLI stock: November 5 results date guides Denali Therapeutics stock

https://www.ad-hoc-news.de/boerse/news/corporate-news/dnli-stock-november-5-results-date-guides-denali-therapeutics-stock/70395001
Denali Therapeutics (DNLI) is projected to report third-quarter 2026 results on November 5, 2026, with a consensus revenue forecast of USD 12.22 million, a significant increase from the previous quarter's USD 3.60 million. The company, which focuses on neurodegenerative diseases, reported a wider-than-expected diluted loss of USD 0.68 per share in Q2. Denali Therapeutics stock was trading at EUR 16.56 at Lang & Schwarz after hours on October 22, 2026, and USD 18.55 on Nasdaq.

Wedbush cuts target to USD 23: Denali Therapeutics stock gains 5.13 percent

https://www.ad-hoc-news.de/boerse/news/nebenwerte/wedbush-cuts-target-to-usd-23-denali-therapeutics-stock-gains-5-13-percent/70377725
Denali Therapeutics saw its stock gain 5.13 percent, trading at EUR 17.01, despite Wedbush cutting its price target from USD 27.00 to USD 23.00 while maintaining an Outperform rating. The company is set to report third-quarter results on November 5, 2026. Denali's stock price is currently closer to its 52-week low than its high, with a market capitalization of USD 3.1 billion.

Wedbush Cuts Price Target on Denali Therapeutics to $23 From $27, Keeps Outperform Rating

https://finance.yahoo.com/markets/stocks/articles/wedbush-cuts-price-target-denali-111453666.html
Wedbush has lowered its price target for Denali Therapeutics (DNLI) to $23 from $27, while maintaining an Outperform rating on the stock. Despite this reduction, the average analyst rating for Denali Therapeutics remains a "buy" with a mean price target of $35.75. The article notes that premium subscription is required to read the full report.
Advertisement

Denali Therapeutics stock sits 28.07 percent above its 52-week low on October 16, 2026

https://www.ad-hoc-news.de/boerse/news/nebenwerte/denali-therapeutics-stock-sits-28-07-percent-above-its-52-week-low-on-october-16-2026/70349753
Denali Therapeutics (DNLI) stock closed at USD 17.61 on October 16, 2026, marking a 3.98 percent decrease from its prior close and standing 28.07 percent above its 52-week low. The company, which specializes in biotechnology for neurological diseases, had a market capitalization of USD 2.8 billion and reported second-quarter 2026 revenue of USD 3.60 million, exceeding consensus estimates, but a wider diluted loss per share than anticipated. Investors are looking forward to the third-quarter 2026 report, expected on November 5, 2026.

Wall Street Zen cuts Denali Therapeutics stock to sell as target averages USD 35.85

https://www.ad-hoc-news.de/boerse/news/nebenwerte/wall-street-zen-cuts-denali-therapeutics-stock-to-sell-as-target-averages/70333145
Wall Street Zen has downgraded Denali Therapeutics (DNLI) stock to "sell," with an average analyst target of USD 35.85, according to MarketBeat. The company's stock was trading at EUR 16.39 on October 15, 2026, up 2.12 percent. Denali is expected to report third-quarter revenue of USD 12.22 million on November 5, 2026.

Wall Street Zen cuts Denali Therapeutics stock to sell as target averages USD 35.85

https://www.ad-hoc-news.de/boerse/news/nebenwerte/wall-street-zen-cuts-denali-therapeutics-stock-to-sell-as-target-averages-usd-35-85/70333145
Wall Street Zen has cut its rating on Denali Therapeutics (DNLI) stock from hold to sell, with an average analyst target of $35.85. The company's stock was trading at EUR 16.39 on October 15, 2026, and is expected to report Q3 2026 revenue of $12.22 million on November 5, 2026. Denali Therapeutics specializes in developing medicines for neurodegenerative and lysosomal diseases.

Denali Therapeutics Inc. (DNLI) latest stock news and headlines

https://uk.finance.yahoo.com/quote/DNLI/news/
This article provides a compilation of recent news and headlines concerning Denali Therapeutics Inc. (DNLI), sourced primarily from Yahoo Finance. It includes various news items from the past few months, such as analyst evaluations, market growth forecasts for related diseases, and financial results like Q2 earnings and revenue. The article also presents current stock performance data and historical returns for DNLI compared to the S&P 500.

Denali Therapeutics Inc. (DNLI) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/DNLI/
This article provides comprehensive financial information for Denali Therapeutics Inc. (DNLI), including its current stock price, historical performance, key financial metrics, and analyst insights. It details the company's focus on developing therapeutics for neurodegenerative and lysosomal storage diseases, listing several of its active programs and partnerships. The report also includes performance comparisons against the S&P 500 and highlights recent earnings and analyst recommendations.
Advertisement

Denali Therapeutics Q2 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/10/62295456/denali-therapeutics-q2-2026-earnings-call-transcript
Denali Therapeutics reported strong Q2 2026 financial results, highlighted by $3.6 million in net product revenue for its new therapy, Avlea, during its first full commercial quarter. The company also advanced two Alzheimer's disease programs (DNL628 and DNL921) into clinical development, with initial data anticipated in 2027. Denali maintains a robust financial position with over $1.1 billion in cash and securities, and expects Q3 net product revenue for Avlea to be between $10 million and $12 million.

Trading the Move, Not the Narrative: (DNLI) Edition

https://news.stocktradersdaily.com/news_release/10/Trading_the_Move,_Not_the_Narrative:_DNLI_Edition_101126094801_1791726481.html
Denali Therapeutics Inc. (NASDAQ: DNLI) is showing weak near and mid-term sentiment, which could challenge its long-term positive outlook. The article provides AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis indicating support and resistance levels.

Is Denali Therapeutics (DNLI) Reasonably Valued On Future Cash Flow?

https://finance.yahoo.com/markets/stocks/articles/denali-therapeutics-dnli-reasonably-valued-032252427.html
Denali Therapeutics (DNLI) has seen a mixed share price performance, with recent gains contrasting a weaker long-term trend. The company's valuation is currently being assessed against its future cash flow potential, particularly given its heavy investment in neurodegenerative disease treatments and current cash outflow. A Discounted Cash Flow (DCF) analysis suggests the estimated intrinsic value is in line with the current market price, prompting investors to consider whether the projected shift from cash burn to consistent inflows is achievable.

Denali Therapeutics (NasdaqGS:DNLI) Stock Forecast & Analyst Predictions

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnli/denali-therapeutics/future
Denali Therapeutics (DNLI) is forecast to grow earnings and revenue significantly, with analysts predicting 28.5% earnings growth and 53.7% revenue growth per annum. The company recently received FDA approval for AVLAYAH for Hunter syndrome and sold a Priority Review Voucher for $195 million, shifting towards commercial operations. Despite promising pipeline advancements and capital raises, the company faces risks including declining past revenues and profitability forecasts, and significant insider selling.

Denali Therapeutics stock stood 29.1 percent below its yearly high

https://www.ad-hoc-news.de/boerse/news/nebenwerte/denali-therapeutics-stock-stood-29-1-percent-below-its-yearly-high/70260557
Denali Therapeutics stock is currently trading 29.1% below its 52-week high, at USD 19.285. The company's Q2 2026 revenue of USD 3.60 million surpassed estimates, though it reported a larger-than-expected diluted EPS loss of USD 0.68. Analysts have a "Moderate Buy" consensus with a high average 12-month price target of USD 35.85, reflecting optimism despite the current valuation challenges tied to the AVLAYAH commercial launch and ongoing research spending.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement